Abstract
INTRODUCTION Little is known about longitudinal decline in white matter (WM) microstructure and its associations with cognition in preclinical Alzheimer’s disease (AD).
METHODS Longitudinal diffusion tensor imaging and neuropsychological testing from 50 older adults who subsequently developed mild cognitive impairment or dementia (subsequently impaired, SI) and 200 cognitively normal controls. Rates of WM decline were compared between groups using voxel-wise linear mixed-effects models. Associations between change in WM and cognition were examined.
RESULTS SI had faster decline in fractional anisotropy (FA) in the right inferior fronto-occipital fasciculus (R.IFOF) and bilateral splenium of the corpus callosum. Decline in R.IFOF FA was related to decline in verbal memory, visuospatial ability, processing speed, and MMSE (p≤ 0.05). Decline in bilateral splenium FA was related to decline in verbal fluency, processing speed, and MMSE (p≤ 0.05).
DISCUSSION Accelerated regional WM decline is characteristic of preclinical AD and related to domain specific cognitive decline.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT00233272
Funding Statement
This research was supported entirely by the Intramural Research Program of the National Institutes of Health, National Institute on Aging.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research protocols were approved by by the National Institute of Environmental Health Sciences (NIEHS) IRB which provided ethical approval. All participants gave written informed consent at each visit.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data from the BLSA are available on request from the BLSA website (http://blsa.nih.gov). All requests are reviewed by the BLSA Data Sharing Proposal Review Committee and are also subject to approval from the NIH institutional review board.
